Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 135: 111186, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33395606

ABSTRACT

Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a neglected tropical disease that is endemic in Latin America and spreading worldwide due to globalization. The current treatments are based on benznidazole and nifurtimox; however, these drugs have important limitations and limited efficacy during the chronic phase, reinforcing the necessity of an alternative chemotherapy. For the last 30 years, our group has been evaluating the biological activity of naphthoquinones and derivatives on T. cruzi, and of the compounds tested, N1, N2 and N3 were found to be the most active in vitro. Here, we show the synthesis of a novel ß-lapachone-derived naphthoimidazolium named N4 and assess its activity on T. cruzi stages and the mechanism of action. The new compound was very active on all parasite stages (IC50/24 h in the range of 0.8-7.9 µM) and had a selectivity index of 5.4. Mechanistic analyses reveal that mitochondrial ROS production begins after short treatment starts and primarily affects the activity of complexes II-III. After 24 h treatment, a partial restoration of mitochondrial physiology (normal complexes II-III and IV activities and controlled H2O2 release) was observed; however, an extensive injury in its morphology was still detected. During treatment with N4, we also observed that trypanothione reductase activity increased in a time-dependent manner and concomitant with increased oxidative stress. Molecular docking calculations indicated the ubiquinone binding site of succinate dehydrogenase as an important interaction point with N4, as with the FMN binding site of dihydroorotate dehydrogenase. The results presented here may be a good starting point for the development of alternative treatments for Chagas disease and for understanding the mechanism of naphthoimidazoles in T. cruzi.


Subject(s)
Chagas Disease/drug therapy , Electron Transport Chain Complex Proteins/metabolism , Energy Metabolism/drug effects , Mitochondria/drug effects , Naphthoquinones/pharmacology , Protozoan Proteins/metabolism , Trypanocidal Agents/pharmacology , Trypanosoma cruzi/drug effects , Chagas Disease/enzymology , Chagas Disease/parasitology , Dihydroorotate Dehydrogenase , Mitochondria/enzymology , Mitochondria/ultrastructure , Mitochondrial Swelling/drug effects , Oxidoreductases Acting on CH-CH Group Donors/metabolism , Reactive Oxygen Species/metabolism , Succinate Dehydrogenase/metabolism , Trypanosoma cruzi/enzymology , Trypanosoma cruzi/growth & development , Trypanosoma cruzi/ultrastructure
2.
Molecules ; 16(2): 1192-200, 2011 Jan 27.
Article in English | MEDLINE | ID: mdl-21273950

ABSTRACT

The compound (10E)-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione-10-oxime (1) was synthesized from a-lapachone and hydroxylamine chloride in alkaline medium. Single-crystals suitable for X-ray diffraction measurements were grown from an ethanol solution, and the crystal structure of the title molecule is reported for the first time. The title molecule was also characterized by ¹H- and ¹³C-NMR in CDCl3 solution, FTIR and MS. The crystal structure of 1 shows an E stereochemistry and dimers formed through classical hydrogen bonds.


Subject(s)
Naphthoquinones/chemistry , Oximes/chemistry , Oximes/chemical synthesis , Crystallography, X-Ray , Hydrogen Bonding , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , X-Ray Diffraction
SELECTION OF CITATIONS
SEARCH DETAIL
...